Connect with us

Micro Cap Insider

Swift Rise of Biotech IPIX (Innovation Pharmaceuticals) as Potent Therapeutic Brilacidin Begins Clinical Trials

Published

on

IPIX (Innovation Pharmaceuticals) is making a major run up the charts in recent weeks making a move towards its June highs of $0.65 per share on fast growing volume topping several million in dollar volume per day. IPIX has been under heavy accumulation recently and volume has picked up substantially since early December as a new era of penny stock speculators fueled by the robinhood app and its brand new 100 million trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than IPIX does. IPIX has a long history of legendary runs skyrocketing to $4.93 per share when it was trading as CTIX. Currently making a move on its recent highs, investors are looking for a break over $0.65 for confirmation of the next big leg up. 

It’s easy to get excited about IPIX; the Company’s flagship Brilacidin is quickly emerging as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19, is one of the few drugs targeting COVID-19 that has been tested in human trials for other clinical indications, providing established safety and efficacy data. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). Earlier this month IPIX began its Phase 2 clinical trial of Brilacidin for treating COVID-19. The Phase 2 randomized, placebo-controlled clinical trial includes approximately 120 hospitalized patients with moderate-to-severe COVID-19. Two intravenous treatment arms were enrolled—active and placebo, with ~60 patients per arm. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) clinical status ordinal scale.  A non-peer-reviewed study recently reported that Brilacidin Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. A peer-reviewed study recently published reported that Brilacidin Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.

Innovation Pharmaceuticals (OTCQB: IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019, who have recently initiated a Phase 1 study with their formulation. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. Brilacidin, based on promising in vitro antiviral activity against SARS-CoV-2, is being evaluated as a potential treatment for COVID-19.  

Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19, is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1β, TNF-α and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential.  

Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”

Investor sentiment in IPIX is high:

IPIX has established a valuable intellectual property portfolio: 

To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPIX

Earlier this month IPIX began its Phase 2 clinical trial of Brilacidin for treating COVID-19. The Phase 2 randomized, placebo-controlled clinical trial includes approximately 120 hospitalized patients with moderate-to-severe COVID-19. Two intravenous treatment arms were enrolled—active and placebo, with ~60 patients per arm. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) clinical status ordinal scale. Other endpoints include: in-hospital outcomes, all-cause mortality, measurement of inflammation-related biomarkers, changes to SARS-CoV-2 viral load, and other key measures. The Company believes Brilacidin holds tremendous promise to help address the global pandemic, particularly given the emergence of contagious and virulent coronavirus variants. Data increasingly are showing these variants can significantly lessen the effectiveness of COVID-19 treatments and vaccines. For example, a Phase 2b trial in South Africa showed the Novavax vaccine was less than 50 percent effective against a new coronavirus variant originally identified in that country. 

A key differentiating aspect of Brilacidin’s antiviral mechanism of action is its ability to attack the coronavirus directly by disrupting viral membrane integrity. This suggests Brilacidin would be less prone to resistance developing due to viral mutations. Brilacidin already has been shown to inhibit the Washington and Italian strains of the coronavirus and multiple strains of endemic human coronaviruses (H-CoVs), with additional laboratory testing of Brilacidin planned against new coronavirus variants. Novel therapeutics with broad-spectrum anti-coronavirus properties are, and will continue to be, much-needed as the world confronts the coronavirus pandemic and prepares for the likelihood of future viral pandemics. 

Recently after the FDA approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19 the Company’s CEO Leo Ehrlich stated: “It’s clear from comments of infectious disease experts like Dr. Anthony Fauci and recent news reports on emerging COVID-19 variants that we are not out of the woods yet with the coronavirus, by any stretch of the imagination. Even with vaccines starting to be rolled-out, it is going to be many more months for them to reach the masses and potentially years before vaccines are available worldwide. There is now and will be into the foreseeable future a real need for new therapeutics to treat people who contract the infection. We have great hopes Brilacidin will emerge as a novel therapeutic to help fight the global pandemic.”

For More on IPIX Subscribe Right Now!

IPIX is making a major run up the charts in recent weeks making a move towards its June highs of $0.65 per share on fast growing volume topping several million in dollar volume per day. IPIX has been under heavy accumulation recently and volume has picked up substantially since early December as a new era of penny stock speculators fueled by the robinhood app and its brand new 100 million trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than IPIX does. IPIX has a long history of legendary runs skyrocketing to $4.93 per share when it was trading as CTIX. Currently making a move on its recent highs, investors are looking for a break over $0.65 for confirmation of the next big leg up. It’s easy to get excited about IPIX; the Company’s flagship Brilacidin is quickly emerging as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19, is one of the few drugs targeting COVID-19 that has been tested in human trials for other clinical indications, providing established safety and efficacy data. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). Earlier this month IPIX began its Phase 2 clinical trial of Brilacidin for treating COVID-19. The Phase 2 randomized, placebo-controlled clinical trial includes approximately 120 hospitalized patients with moderate-to-severe COVID-19. Two intravenous treatment arms were enrolled—active and placebo, with ~60 patients per arm. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) clinical status ordinal scale.  A peer-reviewed study recently published reported that Brilacidin Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.

Continue Reading
1 Comment

1 Comment

  1. John Bach

    February 20, 2021 at 8:27 am

    BOE… sorry to tell you but your article on Innovation Pharmaceuticals and Brilacidin….is incorrect…

    the ARTICLE published from George Mason University … IS “PEER REVIEWED” and published

    see link: https://www.mdpi.com/1999-4915/13/2/271

Leave a Reply

Your email address will not be published. Required fields are marked *

Media & Technology

Global Tech Industries Group Inc (GTII) rally could be just getting started

Published

on

Small-cap stocks have seen a significant increase in the first weeks of January, a trend that is often seen at the start of a new year. This presents an opportunity for investors to capitalize on the surge before it dissipates. The Russell 2000 index, which follows small-cap stocks, has shown a 7.4% increase as of Monday’s close, outperforming the large-cap Russell 1000, which has risen by 5%, and the S&P 500, which has increased by 4.5%.

The “January Effect” rally, where small caps surpass large caps, is a common phenomenon. One such stock that may be benefitting from this January effect is GTII. Global Tech Industries Group Inc (GTII) last traded at $1.86 and closed with double-digit gains of 11.08%.  GTII has a 52-week range of $0.4302 – $8.9700, suggesting a tremendous upside potential from the current levels.

To Find out the inside Scoop on GTII, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What caused the surge in GTII share prices?

For the uninitiated,  Global Tech Industries Group, Inc. (OTCQB: GTII) is a Nevada-based public company focused on acquiring cutting-edge technologies. Last week, GTII announced Board appointed Donald Gilbert to lead a newly created task force that will investigate illegal trading in GTII’s shares. The task force will be responsible for examining and assessing the possibility of illegal and deceptive trading practices by various market players, including market makers, brokers, and hedge funds. In addition, the task force will also advise the Board on potential legal actions against market participants suspected of engaging in unlawful trading activity concerning GTII’s shares. Based on its initial assessment, the task force will also advise the Board on presenting evidence of potential illegal trading activity concerning GTII’s shares to relevant government and regulatory agencies. In essence, Mr. Gilbert will lead the efforts necessary for safeguarding the interests of GTII’s shareholders.

For more on GTII, Subscribe Right Now!

Creatd, Inc.(OTCQB: CRTD) announced today that it had extended the no-shop period in its Letter of Intent with Global Tech Industries Group, Inc. (GTII) for its planned acquisition. Although there’s no guarantee a deal will be reached, both firms continue to evaluate the deal through due diligence, and Creatd is exploring a collar structure to potentially value its shares at $3.00 to $5.00 per share.

It would be interesting to see if GTII news gets picked up by retail investors causing a further surge in stock prices. We will update GTII when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s going on with GTII.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GTII either long or short and we have not been compensated for this article

Continue Reading

Micro Cap Insider

Good Vibrations Shoes Inc. (OTCMKTS: GVSI): The OTC Stock To Own In 2023?

Published

on

Good Vibrations Shoes Inc. (OTCMKTS: GVSI) is perhaps the most-talked-about OTC stock to kick off 2023 as a George Sharp reverse merger penny stock.

Good Vibrations Shoes Inc. (OTCMKTS: GVSI) is perhaps the most-talked-about OTC stock to kick off 2023 as a George Sharp reverse merger penny stock. Many say they won’t sell for less than $.50 a share. They are banking on reverse merger whiz George Sharp to deliver the goods like he did when TSNP merged with HUMBL Inc. (OTCMKTS: HMBL).

As everyone knows, George Sharp is the stock whizz behind some of the biggest runners in recent penny stocks history, including the great TSNP and FORW, which also went from under a penny to $1 plus. For the past 17 years, George Sharp has been a consultant to companies in various contexts, including software development, assisting public companies with growth and regulatory compliance plans. In June 2017, Mr. Sharp was engaged as a consultant by OTC Markets Group, Inc. to develop compliance processes to bring more timely and actionable data to the OTC market. Working with OTCMarkets Group as a consultant for many years gives GS a considerable advantage, and if anyone can make things happen with GVSI, it is George Sharp. 

Reverse mergers can be more explosive than biotechs when the incoming Company has real value but is undiscovered to investors, and many RM stocks that we have covered on this website have gone from pennies to dollars. Microcap Daily was one of the first on the scene as TSNP was taking off, reporting on the stock on November 15, 2020 when TSNP was trading at $0.003, stating at the time:

“TSNP is making a spectacular run up the charts in recent weeks, quickly transforming into a volume leader and one of the top most traded stocks in small caps. TSNP started in triple zero land but has gone parabolic since then, quickly attracting legions of new shareholders who continue to bid the stock higher. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotechs in their ability to make historic gains. TSNP is the perfect merger candidate; a clean shell with virtually no debt, and the new Company HUMBL is a major mobile payments player with a first-class management team with team members coming from companies like Western Union, Moneygram, Visa, American Express, Epson, Microsoft, Facebook and Qualcomm and was recently named a Forbes “Rising Startups to Watch” The merger is being shepherded by well-known OTC Markets analyst George Sharp, who brought the parties together and has provided valuable advice on strategies and compliance to complete the transaction.” We concluded, “The whole deal is being shepherded by George Sharp, a reverse merger whizz and someone known for doing it right.”

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Good Vibrations Shoes Inc. (OTCMKTS: GVSI) is a Nevada corporation, formerly known as Bitcoin Collect, Inc., Solpower Corp., Virtual Technologies, Inc., and Dynafuel Corporation, which was incorporated under the laws of the State of Utah on June 7, 1982. The Company is a perfect reverse merger candidate with a clean balance sheet of just $250k in liabilities.

To Find out the inside Scoop on GVSI, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GVSI

Latest Updates

GVSI should be Pink Current any day now. The Canadians that sold after GVSI came off the Expert Market will be buying back in. Savvy investors that picked up cheapies under $.025 will be rewarded.

GVSI has also filed to cancel shares.

We also have this agreement between GS and GVSI. These are the shares that, on August 29, 2021, in recognition of the $50,000 cash invested and $50,000 in consulting fees accrued by George Sharp for professional and regulatory costs to reinstate the registrant in the State of Nevada and to have the registrant become current in its filings under the SEC’s recently imposed requirements for public companies operating under SEC Rule 15c2-11, the Board issued 300,000 shares of the authorized “blank check” preferred stock to George Sharp with 10,000 votes for each share of preferred stock to give voting control to Mr. Sharp.

For more on GVSI, Subscribe Right Now!

GVSI represents the highest risk-reward in the OTC Markets right now. Some investors have been impatient and sold their shares at these low levels. The key to understanding is that these things take time, TSNP took a long, long time, and GVSI will be all the more exciting. As previously stated, Mr. Sharp was engaged as a consultant by OTC Markets Group, Inc. to develop compliance processes, so if anyone can get it done, he can. Mr. Sharp continues to tweet about GVSI regularly, and it’s listed at the top of his Twitter account. All the uncertainty and bashing have created a unique situation for GVSI; it currently trades under $0.03. If things happen here as GS says they will, this will be one seriously parabolic situation with a massive upside. There are no guarantees on the OTC and no sure thing at all, GVSI is a lottery ticket for sure, but considering GS track record, I would say this is a good ticket. We will update GVSI when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s going on with GVSI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GVSI either long or short and we have not been compensated for this article

Image by WikiImages from Pixabay

Continue Reading

Micro Cap Insider

CeCors Inc (OTCMKTS: CEOS) Opportunity Mushrooms with Disabled Veterans

Published

on

CeCors Inc (OTCMKTS: CEOS) is at heart a mushroom company with products on the shelf that is transforming into a disabled veteran benefits company.  Many have heard of magic mushrooms, psychedelic mushrooms, and psilocybin and their medicinal benefits. One of the biggest consumers of these products is disabled veterans. The core company is PsyKey which is a vertically integrated mushroom company developing medicinal products for healthcare professionals and consumers.  The products come primarily from functional mushrooms that have specific purposes.  Their mushrooms are cleverly mixed with coffee pods as a delivery system that allows people to start their day off right.      

While the company does have modest revenues from the sales of their core products, the sizzle is in the acquisition of VetComm Corp. announced in mid December. The reality was that this binding letter of intent was not taken seriously by market participants until they were beaten over the head with a video with the charismatic CEO of VetComm, Kate Monroe.    

This video outlined her goal of onboarding 1.0 million veterans of the 14 million veterans eligible for disability to get their rating.  If she accomplishes this goal she claims 

“This would put $30 billion per month into the US economy”

The huge problem they are trying to solve is the simplification of the governmental claims process.  These 14 million veterans eligible for benefits simply don’t have the energy to cut through the red tape and get a successful disability rating with the government.  VetCOMM has a seasoned team that essentially handles the rating process for the vets.  All the vets have to do is pay the monthly fee and answer the questions from VetComm.  

1.0 Million Veteran Challenge

Anyone thinking that 1.0 million isn’t attainable is underestimating both the CEO Kate Monroe, a veteran herself from the Marine Corps, and the networking power of veterans. Veterans are a tight knit community.  Think about it some of these vets were sitting in a foxhole and their life depended on their buddy doing his job.  So when these vets sign up for VetComm and get a positive result and then call their buddy up and say trust me you need to do this, there is no waffling around. Vets will listen to other vets.  This video from Randy Couture just shows you a hint of the star power they have behind this company. 

   

The government set aside tens of billions of dollars for disabled veterans but navigating the rating process with the government paper pushers is worse than combat for some of these vets.  They get discouraged and give up, that is where the tenacity of the VetComm team comes into play and knows how to successfully navigate the bureaucratic maze and get results for these veterans. VetComm just takes a flat fee for their service ($247 or $997) and the vets could receive thousands of dollars monthly depending on their level of injury.  There is no reason not to try, and the company has a money back guarantee.  Even more exciting is the back pay some of these vets could receive.  Wait until some of the testimonials go viral.  The website currently has real testimonials from veterans sharing their story of how easy it was to get rated.  The message from VetComm is that there is nothing to lose and almost everyone walks away with something.  

The CEO is a networking guru and has pictures with top politicians and generals all supporting her efforts.  These are top politicians like Senator Ted Cruz, Roger Marshall, Earnest Grassley, John Cornyn, and Deb Fischer. Then there are the celebrity endorsements from Randy Couture, Ken Shamrock, Donald Trump, Jr., Sarah Palin, Matt Thomas of Parmalee, Carl Higbee, and Gretchen Carlson. 

Revenue Estimates

The revenue off of her 1.0 million veteran goal could be $500 million considering that the average fee is about $500 dollars assuming the majority will opt for the do it yourself rating instead of the “Done-For-You” service.  The company has no formal projections but if they do release something it could be a big catalyst. The costs of goods sold on this are marketing and the customer support line.  VetComm is essentially getting a small sliver of the $30 billion monthly pot of money the government has agreed to pay out but hasn’t had to because the veterans haven’t filled out their paperwork.  Kate Monroe is creating a social movement in the veteran community to take what they are owed and not let politicians repurpose those funds for other special interests     

Acquisition Synergy         

There is a sense of community that VetComm is trying to establish.  Many of the vets that suffer from PTSD would be helped by the functional mushroom products.  There is also a planned expansion of the product line that the company alluded to last year.  A natural expansion of the line could mean that other products like gummy bears, capsules, or other delivery systems are introduced.       

Financial Analysis

The company has 332 million shares in the O/S and has 148 million in the float.  The current market cap is sitting at close to $10 million. Since they are an operational company with revenues they had their Shell Status designation removed from OTC Markets.  The company has also openly stated that they are not going to reverse split the stock or take on additional dilution.  This might be interpreted to mean that they won’t exceed the authorized limit of 500 million shares.    

This means the VetComm acquisition is likely to be paid with treasury stock.  In early 2022 87.75 million shares were brought back into treasury and could easily be reissued for the purchase.  This is complete speculation because the details of the acquisition have yet to be released but the bread crumbs lead to a very shareholder friendly transaction.  

Risks

There is a definitive deal to acquire VetComm, but investors are not privy to the terms of the deal. Therein lies the major risk. Investors have no idea how much dilution is possible in the acquisition nor do they know how strong the underlying business is. Dilution would have to be less than the authorized max.  It’s impossible to tell if it’s a good deal or a bad deal, although their comments on social media demonstrate it’s going to be very positive.  Leadership is a question too because there is no CEO at the helm.  The filings show Amar Bhatal is the president and the CEO spot is vacant. While it’s reasonable to speculate that Kate Monroe would be the ideal candidate for CEO, she has no public market experience. If the VetComm acquisition were to fall apart many investors could be holding the bag because the underlying mushroom business has not generated sufficient earnings to support the public listing short term.       

Investor Summary

The volume is just starting to ramp off of what looks like a long term bottom so there doesn’t appear to be much downside at the current stock price and plenty of upside to $.12. The mushroom industry is massive, but a unique opportunity exists in servicing veterans.  VetComm is led by a charismatic CEO who might very well take over CEOS.  Her social media standing suggests that she is going to use digital marketing and the power of veteran networking and endorsements to mobilize the veterans.  This deal can almost be considered a Software as a Service (SaaS) deal as it contains those components.  The goal of attaining 1.0 million veterans by year end could translate into massive revenues in the tens of millions or hundreds of millions with little to no customer acquisition acquisition costs (CAC).  It’s too early to tell, but CEOS is one of those long term fundamental plays that should be held in a speculative portfolio. Should they complete the acquisition and give revenue estimates investors could see long term 12 – 18 month upside up to $1.00 assuming a fully diluted 500 million O/S and $500 million in revenues trading at a multiple of 1X sales. The downside risk is nominal given their rapidly expanding mushroom line that could be cash flow positive on its own this year.  

Disclosure: MicroCapDaily has not been compensated for this article. This post was written by a guest contributor and posted on our website for free. The owners of MicroCapDaily have no position in any of the securities mentioned.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.